Forbes Nod for Daré CEO Lands as DARE Slips Under $1

Daré Bioscience, Inc. (NASDAQ: DARE) said on Aug. 18, 2026 that chief executive Sabrina Martucci Johnson was named to the Forbes 2026 "50 Over 50: Innovation" list, a day after the shares closed at 0.81, down 12.88%.

Daré Bioscience, Inc. (NASDAQ: DARE) told investors on Aug. 18, 2026 that its chief executive, Sabrina Martucci Johnson, had been named to the Forbes 2026 "50 Over 50: Innovation" list. The San Diego company, which describes itself as a purpose-driven health biotech focused solely on closing the gap in women's health between promising science and real-world solutions, distributed the news through GLOBE NEWSWIRE.

It is the kind of announcement that arrives with no financial content attached — no trial readout, no partnership economics, no revenue line. Read on its own, it is a personal honor. Read against the tape, it is a reminder of how far apart reputation and market value can sit for a small-capitalization biotech.

What the share price was doing the day before

Daré stock last traded at 0.81, down 12.88% from the previous close of 0.93, according to licensed market data as of 20:00 GMT on Monday, Aug. 17, 2026. The session range was 0.81 to 0.93 — the stock finished at the bottom of its own band, which is the shape of a day where sellers had the last word rather than one where a decline was bought back.

That drop happened against a broad market that was softer but nothing like as weak. The S&P 500 tracker (SPY) closed at $772.67, down 0.47%. The Nasdaq 100 proxy (QQQ) finished at $729.87, off 0.16%. The Dow 30 fund (DIA) ended at $534.19, down 0.49%. So Daré's move was company-specific, not a market event, and the scale of it — a double-digit percentage decline on a sub-dollar quote — is a reminder that at these price levels a few cents of movement translates into headline percentages.

The sub-dollar level matters for a second reason familiar to anyone who follows micro-cap listings: Nasdaq maintains a minimum bid price requirement for continued listing. Nothing in the company's announcement addresses listing status, and nothing here should be read as a statement that Daré has received any notice. But investors in any stock quoted below a dollar are, in practice, watching that threshold as closely as they watch the science.

Why a Forbes list is a real asset for a company this size

It is easy to dismiss awards coverage as corporate wallpaper. For a company of Daré's profile, it is not quite that. The "50 Over 50" franchise is built around women who reached significant achievement later in a career, and the innovation edition specifically frames its honorees as builders of new things. For a chief executive whose main daily task is convincing investors, partners and licensees to fund long-duration women's health programs, third-party validation of that kind is a recruiting and fundraising tool rather than a vanity item.

Women's health has been chronically underfunded relative to the size of the addressable population, and Daré's own positioning language — closing the gap between promising science and real-world solutions — is an explicit acknowledgment that the bottleneck in the field has often been capital and commercialization rather than discovery. A CEO with national visibility is, in that context, a distribution channel for the story.

What it is not is a substitute for cash flow. The announcement, as reported by Business Insider Markets, carries no update on pipeline timing, financing or partnership terms. Investors should treat it as reputational news and price it accordingly, which is to say close to zero.

How to read award announcements from micro-cap biotech

There is a well-worn pattern in the small end of the biotech market: press-release cadence rises when there is a gap between value-creating events. That is not an accusation against any particular issuer, and executive recognition is legitimately newsworthy. But it does mean the disciplined approach for a shareholder is to sort announcements into two buckets.

Changes the cash math: clinical readouts, regulatory decisions, licensing deals with disclosed economics, equity or debt raises, and reimbursement wins.
Changes the narrative only: conference presentations, awards, index inclusions in non-tradable lists, and leadership recognition.

Monday's close in the low eighties of a cent suggests the market has been focused squarely on the first bucket. A Tuesday-morning honor for the chief executive does not move an item from the second bucket into the first, however deserved it is.

The specific things worth watching next

For anyone following the name, the questions that will actually determine the equity outcome are unchanged by this announcement, and none of them were answered in it:

Runway. How long does existing cash fund operations, and what does the next financing look like at a sub-dollar share price? Dilution risk is the dominant variable at this valuation.
Partnered programs. Whether milestone or royalty income from licensed assets arrives on schedule, and whether disclosed terms improve.
Listing compliance. Whether the bid price recovers above the exchange's minimum, and if not, what remedies the company pursues.
Pipeline catalysts. Any dated readout that gives the market something to underwrite rather than a story to believe.

Recognition of a founder-operator in a field the industry has underserved is worth noting on its own terms. It sits, though, alongside a stock that closed the prior session at the very low of its day, down nearly 13%, and against benchmarks that barely moved. Those two facts are both true, and only one of them shows up in a valuation.

The gap between them is the whole story of the small-cap biotech trade: the science and the leadership can be genuinely well regarded while the equity trades as an option on financing. Investors who own the shares are not buying an award. They are buying the probability that the next capital raise happens on terms that do not erase them, and the probability that a clinical or commercial event arrives first.

Key facts

Ticker and last price: NASDAQ: DARE — 0.81, down 12.88%, as of 20:00 GMT Aug. 17, 2026
Announcement: CEO Sabrina Martucci Johnson named to Forbes 2026 "50 Over 50: Innovation" list, Aug. 18, 2026
Prior close and range: Previous close 0.93; session range 0.81–0.93 (closed at the low)
Benchmarks that session: SPY $772.67 (-0.47%), QQQ $729.87 (-0.16%), DIA $534.19 (-0.49%)

Frequently asked questions

What exactly did Daré Bioscience announce?

On Aug. 18, 2026, the San Diego-based company said via GLOBE NEWSWIRE that its chief executive, Sabrina Martucci Johnson, had been named to the Forbes 2026 "50 Over 50: Innovation" list. The announcement was reputational recognition of the CEO and contained no financial, clinical or partnership information about the business itself.

How did DARE shares perform around the announcement?

Daré Bioscience stock last traded at 0.81, down 12.88% from a previous close of 0.93, as of 20:00 GMT on Aug. 17, 2026, the session before the news. The stock's range that day was 0.81 to 0.93, meaning it finished at the low end of its own trading band.

Did the broader market explain the drop?

No. In the same session the S&P 500 tracker SPY closed at $772.67, down 0.47%, the Nasdaq 100 proxy QQQ at $729.87, down 0.16%, and the Dow 30 fund DIA at $534.19, down 0.49%. A decline of nearly 13% against benchmarks moving less than half a percent points to company-specific pressure.

What does Daré Bioscience do?

The company describes itself as a purpose-driven health biotech focused solely on closing the gap in women's health between promising science and real-world solutions. It is headquartered in San Diego and its common stock is listed on the Nasdaq under the symbol DARE. The Aug. 18 release did not detail individual programs.

Why does a share price below one dollar matter?

Nasdaq maintains a minimum bid price requirement for continued listing, so any stock quoted below a dollar draws attention to that threshold. No listing notice was mentioned in Daré's announcement, and none is implied here, but sub-dollar pricing is one of the standard risks holders of micro-cap equities monitor.

Should investors treat an award as a catalyst?

Executive recognition can help with fundraising, partnering and recruitment, which matters for a small company whose main task is attracting capital. It does not change cash flow, runway or clinical timelines. Investors generally separate announcements that alter the cash math from those that alter only the narrative, and awards fall into the second group.

Sources

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List — Business Insider Markets

Photo: Werner Pfennig · Pexels Licence — source